Skip to main content
Terug
HAE logo

Haemonetics Corporation

Datakwaliteit: 100%
Oversold
HAE
NYSE Healthcare Medical - Instruments & Supplies
€ 55,93
▼ € 0,73 (-1,29%)
Marktkapitalisatie: 2,62B
Dagbereik
€ 55,12 € 57,72
52-Weeksbereik
€ 47,32 € 87,32
Volume
375.879
50D / 200D Gem.
€ 65,06 / € 65,66
Vorige Slotkoers
€ 56,66

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (631 peers)

Metriek Aandeel Sector Mediaan
P/E 15,6 0,2
P/B 3,2 3,0
ROE % 18,8 3,6
Net Margin % 12,3 3,8
Rev Growth 5Y % 11,8 9,9
D/E 1,5 0,2

Koersdoel Analisten

Hold
€ 86,60 +54.8%
Low: € 80,00 High: € 94,00
Forward K/W
11,31
Forward WPA
€ 4,95
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,33B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 7,66
€ 7,54 – € 7,76
 1,76B 3
FY2029 € 6,90
€ 6,79 – € 6,99
 1,64B 3
FY2028 € 5,93
€ 5,52 – € 6,17
 1,49B 5

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-05 € 1,27 € 1,31 +3,1%
2025-11-06 € 1,12 € 1,27 +13,4%
2025-08-07 € 1,01 € 1,10 +8,9%
2025-05-08 € 1,22 € 1,24 +1,6%
2025-02-06 € 1,18 € 1,19 +0,8%
2024-11-07 € 1,09 € 1,12 +2,8%
2024-08-08 € 1,03 € 1,02 -1,0%
2024-05-09 € 0,88 € 0,90 +2,3%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 11,82% annually over 5 years — strong growth
Earnings grew 42,64% over the past year
ROE of 18,83% — decent returns on equity
Generating 142,45M in free cash flow
PEG of 0,44 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 7,87%

Groei

Revenue Growth (5Y)
11,82%
Revenue (1Y)3,95%
Earnings (1Y)42,64%
FCF Growth (3Y)-6,48%

Kwaliteit

Return on Equity
18,83%
ROIC8,13%
Net Margin12,32%
Op. Margin16,30%

Veiligheid

Debt / Equity
1,49
Current Ratio1,62
Interest Coverage22,76

Waardering

P/E Ratio
15,61
Forward P/E11,31
P/B Ratio3,19
EV/EBITDA15,94
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 3,95% Revenue Growth (3Y) 7,91%
Earnings Growth (1Y) 42,64% Earnings Growth (3Y) 20,54%
Revenue Growth (5Y) 11,82% Earnings Growth (5Y) 20,52%
Profitability
Revenue (TTM) 1,36B Net Income (TTM) 167,68M
ROE 18,83% ROA 6,84%
Gross Margin 57,21% Operating Margin 16,30%
Net Margin 12,32% Free Cash Flow (TTM) 142,45M
ROIC 8,13% FCF Growth (3Y) -6,48%
Safety
Debt / Equity 1,49 Current Ratio 1,62
Interest Coverage 22,76
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 15,61 Forward P/E 11,31
P/B Ratio 3,19 P/S Ratio 1,92
PEG Ratio 0,44 Forward PEG N/A
EV/EBITDA 15,94 Fwd EV/EBITDA 8,28
Forward P/S 1,98 Fwd Earnings Yield 8,84%
FCF Yield 5,44%
Market Cap 2,62B Enterprise Value 3,54B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 1,36B 1,31B 1,17B 993,20M 870,46M
Net Income 167,68M 117,56M 115,40M 43,38M 79,47M
EPS (Diluted) 3,31 2,29 2,24 0,84 1,55
Gross Profit 778,55M 711,92M 622,87M 530,77M 428,45M
Operating Income 221,82M 164,88M 156,03M 80,75M 89,75M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 2,45B 2,20B 1,93B 1,86B 1,82B
Total Liabilities 1,63B 1,24B 1,12B 1,11B 1,09B
Shareholders' Equity 820,84M 959,96M 818,00M 749,42M 731,67M
Total Debt 1,22B 807,79M 765,89M 780,79M 778,28M
Cash & Equivalents 306,76M 178,80M 284,47M 259,50M 192,31M
Current Assets 934,98M 768,90M 769,72M 756,03M 693,55M
Current Liabilities 578,11M 300,38M 251,82M 442,27M 253,50M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth + Value Growth at a Reasonable Price (Peter Lynch)
#158 of 327
52

Recente Activiteit

Ingestapt Growth at a Reasonable Price (Peter Lynch)
Mar 24, 2026